Payment overview · 2025
General Payments
$394.22
19 reported records · 16 companies
Healthcare provider profile · identity verified
Adam D Robinson, DO
Allopathic & Osteopathic Physicians|Internal Medicine · COLORADO SPRINGS, CO · NPI 1326300682
Verified facts
What the public records show
CMS Open Payments records show Adam D Robinson, DO received $394.22 in general payments during 2025 across 19 reported records.
Amgen Inc. accounted for 12.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.31 | 12.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.19 | 9.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.42 | 8.7% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $29.52 | 7.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.26 | 6.9% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $27.00 | 6.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.59 | 5.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.32 | 5.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.27 | 5.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.73 | 5.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $19.63 | 5.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.55 | 4.7% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $18.52 | 4.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.52 | 4.4% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $16.77 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.62 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $394.22 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $32.80 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 207 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 43 |
| Lisinopril | Lisinopril | 139 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 111 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 30 |
| Omeprazole | Omeprazole | 92 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 25 |
| Losartan Potassium | Losartan Potassium | 84 | 26 |
| Metformin Hcl | Metformin Hcl | 81 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 20 |
| Gabapentin | Gabapentin | 66 | 24 |
| Trazodone Hcl | Trazodone Hcl | 64 | 20 |
| Allopurinol | Allopurinol | 55 | 17 |
| Furosemide | Furosemide | 51 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 21 |
| Simvastatin | Simvastatin | 48 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Carvedilol | Carvedilol | 43 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Eliquis | Apixaban | 36 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Ozempic | Semaglutide | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 11 |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 11 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $394.22 · 19 records | Amgen Inc. | ABRYSVO, APTIMA, AYVAKIT, BEXSERO, COMIRNATY, Dexcom G6 Transmitter, Doc Band, GVOKE HYPOPEN, KRYSTEXXA, OTEZLA, Ozempic, PEDIARIX, PREVNAR 20, Prolastin-C Liquid, QULIPTA, REPATHA, ROTARIX, Rybelsus, SYMPLICITY G3, THINPREP 2000 PROCESSOR, TZIELD, UBRELVY, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error